Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more
Time Frame | VOR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.18% | -3.39% | -3.47% |
1-Month Return | 13.81% | -3.25% | -0.29% |
3-Month Return | -4.71% | -11.61% | 4.5% |
6-Month Return | -25.83% | -5.89% | 6.91% |
1-Year Return | -61.14% | 2.65% | 23.79% |
3-Year Return | -92.72% | 0.56% | 28.43% |
5-Year Return | -97.63% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 91.00K | 1.39M | 4.45M | 8.96M | 3.49M | [{"date":"2019-12-31","value":1.02,"profit":true},{"date":"2020-12-31","value":15.48,"profit":true},{"date":"2021-12-31","value":49.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.97,"profit":true}] |
Gross Profit | (91.00K) | (1.39M) | (4.45M) | (8.96M) | (3.49M) | [{"date":"2019-12-31","value":-9100000,"profit":false},{"date":"2020-12-31","value":-138700000,"profit":false},{"date":"2021-12-31","value":-445100000,"profit":false},{"date":"2022-12-31","value":-896000000,"profit":false},{"date":"2023-12-31","value":-349200000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 10.42M | 43.37M | 69.02M | 93.42M | 126.04M | [{"date":"2019-12-31","value":8.27,"profit":true},{"date":"2020-12-31","value":34.41,"profit":true},{"date":"2021-12-31","value":54.76,"profit":true},{"date":"2022-12-31","value":74.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (10.42M) | (43.37M) | (69.02M) | (93.42M) | (126.04M) | [{"date":"2019-12-31","value":-1041700000,"profit":false},{"date":"2020-12-31","value":-4336600000,"profit":false},{"date":"2021-12-31","value":-6901800000,"profit":false},{"date":"2022-12-31","value":-9341800000,"profit":false},{"date":"2023-12-31","value":-12603600000,"profit":false}] |
Total Non-Operating Income/Expense | (876.00K) | 58.00K | 238.00K | 2.65M | 15.30M | [{"date":"2019-12-31","value":-5.73,"profit":false},{"date":"2020-12-31","value":0.38,"profit":true},{"date":"2021-12-31","value":1.56,"profit":true},{"date":"2022-12-31","value":17.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (10.84M) | (43.34M) | (68.90M) | (92.09M) | (117.86M) | [{"date":"2019-12-31","value":-1083900000,"profit":false},{"date":"2020-12-31","value":-4333700000,"profit":false},{"date":"2021-12-31","value":-6889900000,"profit":false},{"date":"2022-12-31","value":-9209400000,"profit":false},{"date":"2023-12-31","value":-11786300000,"profit":false}] |
Income Taxes | 608.00K | 427.70K | (119.00K) | (1.32M) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.35,"profit":true},{"date":"2021-12-31","value":-19.57,"profit":false},{"date":"2022-12-31","value":-217.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (11.45M) | (43.76M) | (68.78M) | (90.77M) | - | [{"date":"2019-12-31","value":-1144700000,"profit":false},{"date":"2020-12-31","value":-4376470300,"profit":false},{"date":"2021-12-31","value":-6878000000,"profit":false},{"date":"2022-12-31","value":-9077000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (10.84M) | (43.34M) | (68.90M) | (92.09M) | (115.51M) | [{"date":"2019-12-31","value":-1083900000,"profit":false},{"date":"2020-12-31","value":-4333700000,"profit":false},{"date":"2021-12-31","value":-6889900000,"profit":false},{"date":"2022-12-31","value":-9209400000,"profit":false},{"date":"2023-12-31","value":-11551200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (11.45M) | (43.34M) | (68.78M) | (90.77M) | (117.86M) | [{"date":"2019-12-31","value":-1144700000,"profit":false},{"date":"2020-12-31","value":-4333700000,"profit":false},{"date":"2021-12-31","value":-6878000000,"profit":false},{"date":"2022-12-31","value":-9077000000,"profit":false},{"date":"2023-12-31","value":-11786300000,"profit":false}] |
EPS (Diluted) | (8.08) | (233.56) | (2.15) | (2.34) | (1.76) | [{"date":"2019-12-31","value":-808.3,"profit":false},{"date":"2020-12-31","value":-23355.88,"profit":false},{"date":"2021-12-31","value":-215,"profit":false},{"date":"2022-12-31","value":-234,"profit":false},{"date":"2023-12-31","value":-176,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VOR | |
---|---|
Cash Ratio | 4.38 |
Current Ratio | 4.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VOR | |
---|---|
ROA (LTM) | -39.74% |
ROE (LTM) | -78.07% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VOR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.37 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.63 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VOR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.92 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Vor Biopharma Inc (VOR) share price today is $0.878
Yes, Indians can buy shares of Vor Biopharma Inc (VOR) on Vested. To buy Vor Biopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VOR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vor Biopharma Inc (VOR) via the Vested app. You can start investing in Vor Biopharma Inc (VOR) with a minimum investment of $1.
You can invest in shares of Vor Biopharma Inc (VOR) via Vested in three simple steps:
The 52-week high price of Vor Biopharma Inc (VOR) is $3.14. The 52-week low price of Vor Biopharma Inc (VOR) is $0.63.
The price-to-earnings (P/E) ratio of Vor Biopharma Inc (VOR) is
The price-to-book (P/B) ratio of Vor Biopharma Inc (VOR) is 0.92
The dividend yield of Vor Biopharma Inc (VOR) is 0.00%
The market capitalization of Vor Biopharma Inc (VOR) is $67.05M
The stock symbol (or ticker) of Vor Biopharma Inc is VOR